Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myokardia Inc Cm ST (MYOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,738,859
  • Shares Outstanding, K 40,271
  • Annual Sales, $ 22,500 K
  • Annual Income, $ -45,950 K
  • 36-Month Beta 2.49
  • Price/Sales 45.66
  • Price/Cash Flow N/A
  • Price/Book 4.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.46
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.59
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -119.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.01 +11.18%
on 02/13/19
45.35 -4.37%
on 01/23/19
-1.02 (-2.30%)
since 01/22/19
3-Month
39.01 +11.18%
on 02/13/19
63.76 -31.98%
on 12/03/18
-12.95 (-22.99%)
since 11/21/18
52-Week
39.01 +11.18%
on 02/13/19
67.79 -36.02%
on 10/01/18
-13.88 (-24.24%)
since 02/22/18

Most Recent Stories

More News
Zacks.com featured highlights include: Athene, MyoKardia and Euronav

Zacks.com featured highlights include: Athene, MyoKardia and Euronav

ATH : 44.75 (+0.67%)
EURN : 8.02 (+1.39%)
MYOK : 43.42 (+0.56%)
3 Earnings Acceleration Stocks You Really Need to Look At

Studies have shown that a majority of successful stocks had seen acceleration in earnings before an uptick in the stock price.

ATH : 44.75 (+0.67%)
EURN : 8.02 (+1.39%)
MYOK : 43.42 (+0.56%)
Market Trends Toward New Normal in Duke Energy, VICI Properties, MyoKardia, FLIR, TIER REIT, and ChannelAdvisor -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Duke Energy Corporation...

VICI : 21.68 (+0.09%)
TIER : 24.35 (+0.41%)
DUK : 90.08 (+0.55%)
MYOK : 43.42 (+0.56%)
ECOM : 13.31 (+1.14%)
FLIR : 52.57 (+0.61%)
MyoKardia Appoints William Fairey as Chief Commercial Officer

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment...

MYOK : 43.42 (+0.56%)
MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive...

JPM : 105.26 (-0.20%)
MYOK : 43.42 (+0.56%)
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to...

MYOK : 43.42 (+0.56%)
February 2019 Options Now Available For MyoKardia (MYOK)

Investors in MyoKardia Inc saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MYOK options chain for the...

MYOK : 43.42 (+0.56%)
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients

MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies

MYOK : 43.42 (+0.56%)
Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MyoKardia, Inc. (NASDAQ:MYOK),...

BRS : 1.45 (+2.84%)
CATB : 4.88 (+1.67%)
CASA : 9.16 (-23.41%)
CHEF : 31.72 (-0.88%)
EPE : 0.67 (-1.47%)
MYOK : 43.42 (+0.56%)
MyoKardia Presents Preclinical Evidence of Mavacamten's Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions

Improved Left Ventricular Compliance Demonstrated in Genetic Pig Model of Non-Obstructed Hypertrophic Cardiomyopathy

MYOK : 43.42 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYOK with:

Business Summary

MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility...

See More

Key Turning Points

2nd Resistance Point 44.19
1st Resistance Point 43.69
Last Price 43.42
1st Support Level 42.57
2nd Support Level 41.95

See More

52-Week High 67.79
Fibonacci 61.8% 56.79
Fibonacci 50% 53.40
Fibonacci 38.2% 50.00
Last Price 43.42
52-Week Low 39.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar